Belantamab Mafodotin (Blenrep) for the Management of Multiple Myeloma

This document provides guidance on the use, management, and monitoring of belantamab mafodotin (Blenrep) for treating relapsed/refractory multiple myeloma. It covers dosing, modifications for adverse reactions, supportive care, and monitoring requirements, including the Blenrep REMS program due to ocular toxicity risks. The document also outlines patient-centered activities, including counseling on risks and necessary precautions, and provides additional resources for patients.